Reata Pharmaceuticals Inc to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10 2023

PLANO, Texas–(BUSINESS WIRE)– Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an…Read More